Alzheimer’s Drugs Market Report by Drug Class (Donepezil, Galantamine, Rivastigmine, Memantine, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others), and Region 2024-2032

Alzheimer’s Drugs Market Report by Drug Class (Donepezil, Galantamine, Rivastigmine, Memantine, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others), and Region 2024-2032

Report Format: PDF+Excel | Report ID: SR112024A2695
Buy Now

Market Overview:

The global Alzheimer’s drugs market size reached US$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.3% during 2024-2032. The rising prevalence of Alzheimer’s disease, numerous advancements in drug development, and increasing public and private funding for neurodegenerative disease research are some of the major factors propelling the market.

Report Attribute
Key Statistics
Base Year
Forecast Years
Historical Years
Market Size in 2023 US$ 7.7 Billion
Market Forecast in 2032 US$ 12.4 Billion
Market Growth Rate (2024-2032)

Alzheimer’s drugs refer to pharmaceutical compounds and therapies specifically designed to mitigate the symptoms or slow the progression of Alzheimer’s disease, a prevalent neurodegenerative disorder that primarily affects cognitive functions. They aim to address the underlying pathophysiological changes in the brain, such as the accumulation of amyloid plaques and tau tangles, which are characteristic of Alzheimer’s disease. They fall into two main categories, including cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors, like donepezil, rivastigmine, and galantamine, work by boosting the levels of neurotransmitters in the brain, enhancing cognitive function temporarily. NMDA receptor antagonists, such as memantine, regulate glutamate activity, aid in providing relief from cognitive and behavioral symptoms.

Global Alzheimer’s Drugs Market

The rising prevalence of Alzheimer’s disease that necessitates effective treatments will stimulate the growth of the Alzheimer’s drugs market during the forecast period. Moreover, the increasing research and development efforts by key players due to numerous advancements in neuroscience and a deeper understanding of the disease's underlying mechanisms, leading to the discovery of potential therapeutic agents, is positively influencing market growth. Additionally, the rise in funding allocations by governments and organizations for neurodegenerative disease research, facilitating a conducive environment for drug development, has catalyzed market growth. Besides this, the expanding aging population, particularly in developed regions, is propelling market growth as the elderly are more susceptible to Alzheimer’s disease. Furthermore, the escalating regulatory approvals for novel drugs and therapies that creates opportunities for pharmaceutical companies to enter and expand their presence is contributing to market growth.

Alzheimer’s Drugs Market Trends/Drivers:

Rising prevalence of the disease

The escalating prevalence of Alzheimer’s disease is one of the key factors supporting the market growth. This can be attributed to the rapidly aging population worldwide. As people live longer, the incidence of age-related neurodegenerative disorders, including Alzheimer’s, has surged. This demographic shift places an ever-increasing burden on global healthcare systems and necessitates effective treatments. Pharmaceutical companies are responding to this demand by investing in the development of drugs that can alleviate symptoms or potentially slow down disease progression. Moreover, heightened awareness and early diagnosis contribute to the rising prevalence as more cases are identified. As a result, the prevalence factor drives the market and underscores the urgent need for research and innovation to address the healthcare challenges posed by Alzheimer’s disease.

Rapid advancements in research

Advances in the understanding of Alzheimer’s disease at the molecular and cellular levels are pivotal drivers in the market. Researchers are unraveling the complex mechanisms behind the disease, including the role of amyloid plaques and tau protein tangles in brain degeneration. These insights provide valuable targets for drug development. Additionally, genetics research is revealing the hereditary factors that increase susceptibility to Alzheimer’s, further guiding drug discovery efforts. Cutting-edge technologies, such as genomics, neuroimaging, and biomarker analysis, are facilitating clinical trials and drug efficacy assessments. These research-driven developments are instrumental in expanding the repertoire of potential Alzheimer’s drugs and enhancing their effectiveness, offering hope for improved patient outcomes.

Increasing government funding and support

Governments and healthcare organizations across the globe are increasingly recognizing Alzheimer’s disease as a public health crisis. The substantial economic and social impact of the disease, including caregiver burden and healthcare costs, has led to a rise in funding for Alzheimer’s research and drug development initiatives. Government grants, research partnerships, and incentives for pharmaceutical companies have become more prevalent. This financial support bolsters ongoing research efforts and encourages the pharmaceutical industry to invest in Alzheimer’s drug development. Moreover, regulatory agencies are streamlining approval processes for Alzheimer’s drugs, facilitating faster market entry. In this collaborative environment of public and private sector support, pharmaceutical companies are incentivized to innovate and bring effective Alzheimer’s treatments to the market, addressing a pressing global healthcare need.

Alzheimer’s Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global Alzheimer’s drugs market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

Alzheimer’s Drugs Market

  • Donepezil
  • Galantamine
  • Rivastigmine
  • Memantine
  • Others

Donepezil represents the most popular drug class

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes donepezil, galantamine, rivastigmine, memantine, and others. According to the report, donepezil represented the largest segment.

Donepezil is a medication categorized as a cholinesterase inhibitor, commonly used in the treatment of Alzheimer’s disease. It works by increasing the levels of certain neurotransmitters in the brain, helping to improve cognitive function and alleviate some of the symptoms associated with Alzheimer’s, such as memory loss, confusion, and problems with thinking and reasoning.

Furthermore, donepezil, along with similar drugs like rivastigmine and galantamine, plays a pivotal role in driving the market growth. These drugs are often prescribed to patients with Alzheimer’s to manage their symptoms, providing relief and enhancing their quality of life. As the global prevalence of Alzheimer’s continues to rise, there is an increasing demand for such drugs. This growing demand encourages pharmaceutical companies to invest in research and development, striving to innovate and improve upon existing treatments, thus contributing to the expansion of the Alzheimer’s drugs market.

Breakup by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores
  • Others

Hospital pharmacy accounts for the majority of the market share

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacy, retail pharmacy, online stores, and others. According to the report, hospital pharmacy accounted for the largest market share.

Hospital pharmacy refers to the specialized pharmacy practice within healthcare institutions, such as hospitals and medical centers. Its primary role is to ensure the safe and effective use of medications for inpatients and outpatients. Hospital pharmacists work closely with healthcare teams to provide medication therapy management, including drug dispensing, monitoring, and patient education. Hospital pharmacies play a crucial role in fueling the market expansion as they are instrumental in the distribution and administration of Alzheimer’s medications. They serve as a pivotal link between pharmaceutical companies, healthcare providers, and patients, ensuring that Alzheimer’s drugs reach the right individuals at the right time.

Moreover, hospital pharmacists contribute to patient education and adherence, optimizing the effectiveness of these drugs. The growth of the Alzheimer’s drugs market is related to the efficient and patient-focused services provided by hospital pharmacies, as they facilitate the delivery of these vital medications to those in need.

Breakup by Region:

Alzheimer’s Drugs Market 

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a significant and growing geriatric population, and Alzheimer’s primarily affects older individuals. This demographic trend increases the demand for Alzheimer’s drugs. Moreover, North America boasts a robust healthcare infrastructure, which includes advanced research facilities and pharmaceutical companies at the forefront of Alzheimer’s drug development. These companies conduct clinical trials and research initiatives that contribute to innovation in the field.

Additionally, regulatory bodies like the FDA in the United States play a crucial role in drug approvals, setting the standard for global markets. Apart from this, North America has a high level of awareness about Alzheimer’s disease, leading to early diagnosis and greater use of available treatments. Furthermore, North America's well-established healthcare reimbursement systems and patient advocacy groups actively support access to Alzheimer’s drugs, fostering an environment that drives market growth and encourages pharmaceutical innovation in the region.

Competitive Landscape:

Key players in the Alzheimer’s drugs industry have been instrumental in driving recent innovations. Notably, a groundbreaking FDA-approved drug from one of these major pharmaceutical companies directly targets amyloid plaques, marking a significant advancement in Alzheimer’s treatment. Other key players are pioneering therapies that enhance amyloid clearance and simultaneously address tau pathology, both of which have shown promise in clinical trials. Beyond traditional drug development, these companies are exploring innovative approaches, including anti-inflammatory drugs, to combat neuroinflammation associated with Alzheimer’s. Additionally, digital health technologies have been integrated into their strategies, with the introduction of cognitive assessment tools and digital biomarkers, revolutionizing early detection and monitoring of Alzheimer’s. The efforts of these industry players signify a dynamic and comprehensive approach to tackle this complex neurodegenerative disease.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Daiichi Sankyo Company Limited
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • H. Lundbeck A/S
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Novartis AG
  • Ono Pharmaceutical Co. Ltd.
  • Pfizer Inc
  • Teva Pharmaceutical Industries Limited

Recent Developments:

  • In July 2023, AbbVie Inc., a leading global biopharmaceutical company, announced the expansion of its strategic collaboration with Calibr, a nonprofit drug discovery division of Scripps Research. This collaboration aims to propel the development of multiple preclinical and early-stage clinical assets in the field of biopharmaceuticals. Building upon their existing partnership, this expansion signifies a commitment to advancing innovative therapies for various diseases.
  • In March 2021, Biogen Inc. and Eisai Co., Ltd. expanded their existing collaboration agreement on the treatments of Alzheimer’s disease. This expansion underscores their shared commitment to addressing one of the most challenging and pressing healthcare issues of our time. Both companies bring unique strengths to the table: Biogen's expertise in neuroscience and drug development, combined with Eisai's deep-rooted knowledge in the field of dementia and Alzheimer’s disease, creates a powerful synergy.
  • In September 2022, Eisai Co., Ltd. and Biogen Inc. reported positive topline results from their global Phase 3 Clarity AD clinical trial of lecanemab. Lecanemab is an investigational antibody designed to target amyloid beta (Aβ) protofibrils, and it holds promise as a potential treatment for individuals with mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease. This development marks a significant milestone in the pursuit of effective Alzheimer’s treatments. The positive results suggest that lecanemab has shown potential in addressing the underlying pathology of Alzheimer’s disease by targeting Aβ protofibrils, which are thought to contribute to disease progression.

Alzheimer’s Drugs Market Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Scope of the Report Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Drug Class
  • Distribution Channel
  • Region
Drug Classes Covered Donepezil, Galantamine, Rivastigmine, Memantine, Others
Distribution Channels Covered Hospital Pharmacy, Retail Pharmacy, Online Stores, Others
Regions Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered AbbVie Inc., AstraZeneca PLC, Biogen Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc, Teva Pharmaceutical Industries Limited, etc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

  • How has the global alzheimer’s drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global alzheimer’s drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global alzheimer’s drugs market and who are the key players?
  • What is the degree of competition in the industry?

Key Benefits for Stakeholders:

  • IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Alzheimer’s drugs market from 2018-2032.
  • The research report provides the latest information on the market drivers, challenges, and opportunities in the global Alzheimer’s drugs market.
  • The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
  • Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Alzheimer’s drugs industry and its attractiveness.
  • Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Alzheimer’s Drugs Market Report by Drug Class (Donepezil, Galantamine, Rivastigmine, Memantine, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Stores, and Others), and Region 2024-2032
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-713-2163


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More